Abstract
Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4 – 8 months post-diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 23 February 1998
Rights and permissions
About this article
Cite this article
Yeo, C., Cameron, J. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Chir 383, 129–133 (1998). https://doi.org/10.1007/s004230050104
Issue Date:
DOI: https://doi.org/10.1007/s004230050104